|
|
|
|
|
|
|
|
|
24.03.26 - 12:03
|
Spectral Medical and Vantive Announce Publication of Complete Results from Spectral′s Tigris Trial in the Lancet Respiratory Medicine (GlobeNewswire EN)
|
|
|
TORONTO and DEERFIELD, Ill., March 24, 2026 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, and Vantive, a vital organ therapy company committed to pursuing novel diagnostic and therapeutic options for organ failure, today announced the publication of the complete results from the Tigris trial in The Lancet Respiratory Medicine, a leading peer-reviewed journal in critical care medicine. The randomized-controlled trial evaluated the use of Polymyxin B Hemoadsorption (“PMX”) in adults with endotoxic septic shock, providing a more complete picture of patient outcomes, including survival and safety over time....
|
|
|
26.02.26 - 13:33
|
Spectral Medical Provides Update on PMA Submission Timing for PMX-20R (GlobeNewswire EN)
|
|
|
TORONTO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today provided an update on the timing of its Premarket Approval (“PMA”) submission to the U.S. Food and Drug Administration (“FDA”) for its hemoadsorption device to treat endotoxic septic shock....
|
|
|
|
|
|
|
29.09.25 - 17:24
|
Spectral Medical Inc. Files Base Shelf Prospectus and Revised AIF (GlobeNewswire EN)
|
|
|
TORONTO, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, announced that it has filed a final short form base shelf prospectus (the “Base Shelf Prospectus”) with the securities regulatory authorities in each of the provinces of Canada, except Québec (the “Securities Regulators”) on September 26, 2025 (the “Effective Date”)....
|
|
|
|
|
08.09.25 - 14:03
|
Spectral Medical Sponsors Unite for Sepsis Symposium, Chicago September 8 – 9, 2025 (GlobeNewswire EN)
|
|
|
TORONTO, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced its sponsorship of the Unite for Sepsis Symposium, taking place September 8 – 9, 2025, in Chicago, Illinois. The Company also announced that Debra Foster, Clinical Consultant at Spectral Medical, will participate in a featured session during the event....
|
|
|
25.08.25 - 13:33
|
Spectral Medical Receives US$3 Million From Vantive (GlobeNewswire EN)
|
|
|
TORONTO, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced that it has received the US$3 million Tranche B advance from Vantive US Healthcare LLC (“Vantive”) pursuant to the previously disclosed senior secured promissory note entered into in May 2025....
|
|
|
13.08.25 - 15:39
|
XFRA: SD4: Wiederaufnahme/Resumption (XETRA)
|
|
|
FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.
THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:
INSTRUMENT NAME KUERZEL/SHORTCODE ISIN
SPECTRAL MEDICAL SD4 CA8475771033
AB/FROM ONWARDS 13.08.2025 15:33 CET...
|
|
|
13.08.25 - 08:33
|
XFRA: SD4: Aussetzung/Suspension (XETRA)
|
|
|
DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:
THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:
INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTIL
SPECTRAL MEDICAL SD4 CA8475771033 BAW/UFN...
|
|
|
|
|
|
|
|
|
|
|
04.07.25 - 21:12
|
Spectral Medical Inc. Announces Filing of Base Shelf Prospectus (GlobeNewswire EN)
|
|
|
TORONTO, July 04, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced that it has filed a preliminary short form base shelf prospectus with the securities regulatory authorities in each of the provinces of Canada, except Québec (the “Securities Regulators”)....
|
|
|
06.06.25 - 17:03
|
Spectral Medical Inc. Announces Results of Annual Meeting of Shareholders (GlobeNewswire EN)
|
|
|
TORONTO, June 06, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. ("Spectral" or the "Company") (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced the results of its Annual Meeting of shareholders (the "Shareholders") held yesterday on June 5, 2025 (the "Meeting"). The Company confirms that all resolutions put forward in the Management Information Circular dated April 17, 2025 (the "Circular") to its Shareholders were approved....
|
|
|
16.05.25 - 14:03
|
Spectral Medical to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference (GlobeNewswire EN)
|
|
|
TORONTO, May 16, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced that management will participate in a fireside chat at the 3rd Annual H.C. Wainwright BioConnect Investor Conference, on Tuesday, May 20, 2025 at 11:30 a.m. ET at the Nasdaq headquarters in New York City, New York....
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
